KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Payables: 2009-2025

Historic Payables for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $152.2 million.

  • Jazz Pharmaceuticals' Payables rose 78.20% to $152.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.4 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of $77.9 million for FY2024, which is 24.22% down from last year.
  • Jazz Pharmaceuticals' Payables amounted to $152.2 million in Q3 2025, which was up 70.34% from $89.4 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Payables' 5-year high stood at $152.2 million during Q3 2025, with a 5-year trough of $63.8 million in Q3 2021.
  • Its 3-year average for Payables is $101.4 million, with a median of $97.1 million in 2024.
  • Its Payables has fluctuated over the past 5 years, first soared by 272.23% in 2021, then crashed by 35.45% in 2024.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Payables stood at $100.3 million in 2021, then decreased by 9.51% to $90.8 million in 2022, then rose by 13.21% to $102.8 million in 2023, then decreased by 24.22% to $77.9 million in 2024, then soared by 78.20% to $152.2 million in 2025.
  • Its last three reported values are $152.2 million in Q3 2025, $89.4 million for Q2 2025, and $95.9 million during Q1 2025.